U.S., April 16 -- ClinicalTrials.gov registry received information related to the study (NCT07530380) titled 'UCAR T-cell Therapy Targeting CD19/BCMA in Relapsed/Refractory Autoimmune Hemolytic Anemia' on April 08.
Brief Summary: This is an investigator-initiated trial to evaluate the safety and efficacy of universal allogeneic anti-CD19/BCMA CAR T-cells in AIHA who have failed >= 3 lines of therapy
Study Start Date: April, 2026
Study Type: INTERVENTIONAL
Condition:
AIHA - Warm Autoimmune Hemolytic Anemia
UCART
Intervention:
BIOLOGICAL: QT-219C Cell Injection
A single injection of UCAR T-cells, referred to as universal allogeneic anti-CD19/BCMA CAR T-cells.
Recruitment Status: RECRUITING
Sponsor: The Second Hospital of Anhui Medic...